DprE1 抑制剂的结构-活性关系介导的分子洞察力:综合性审查
Swagatika Dash1, Ekta Rathi1, Avinash Kumar1
1Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Journal of biomolecular structure & dynamics
|July 3, 2023
概括
新出现的耐药结核病需要新的治疗方法. 本综述探讨了Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) 抑制剂,详细介绍了新药发现的结构-活性关系.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 生物化学 生物化学
背景情况:
- 多药耐药结核病 (MDR-TB),广泛耐药结核病 (XDR-TB) 和完全耐药结核病 (TDR-TB) 构成了全球重大卫生挑战.
- 脱烯 fosforyl-β-D-ribose 2′-epimerase (DprE1) 酶是一种用于结核病治疗的新型和验证的药物标.
- DprE1及其异型DprE2对于合成Decaprenylphosphoryl arabinose (DPA) 至关重要,它是菌根菌细胞壁中阿拉比诺 (AG) 和利波阿拉比诺 (LAM) 的前体.
研究的目的:
- 审查已知的DprE1抑制剂的结构活性关系 (SAR).
- 阐明DprE1抑制所必需的药理特征.
- 总结一下在体研究中识别了参与抑制剂相互作用的关键氨基酸残留物.
主要方法:
- 基于目标和基于全细胞的查研究的文献综述.
- 报告的共价和非共价DprE1抑制剂的分析.
- 检查详细介绍分子相互作用的in-silico研究.
主要成果:
- 多种异环和芳香基架已被确定为DprE1抑制剂.
- 对于DprE1抑制剂,观察到共价和非共价结合模式.
- 在体研究中发现了特定的氨基酸残留物,这些残留物对抑制剂的结合和有效性至关重要.
结论:
- 了解DprE1抑制剂的SAR对于开发新的抗结核药物至关重要.
- 对于对抗耐药结核菌株而言,DprE1仍然是一个有希望的目标.
- 进一步研究DprE2的药物可用性可能会提供额外的治疗途径.
更多相关视频
相关概念视频
Structure-Activity Relationships and Drug Design
789
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
789
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.1K
Prodrugs
2.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.7K
Regulation of the Unfolded Protein Response
2.5K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.5K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
608
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
608


